Dropper adding fluid to lab vials

Research and Innovation
For Addressing Pregnancy Related
Concerns and Prenatal Care

As the Pregnancy Company, we view it as our role to demonstrate tangible meaning from scientific innovation. Behind each of our tests is an expectant mother vigilantly protecting her baby, a healthcare practitioner seeking to build fortresses around her patients, and an unborn baby with a lifetime of unbridled potential.

We remain focused on delivering pivotal and actionable information to pregnant women, their physicians, and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs.

PreTRM Researcher wearing lab gear

Scientific Rigor for the Sake of Moms and Babies

Our testing process seeks to uphold the highest level of quality. We are a Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited, and New York State approved laboratory performing the PreTRM Test for all 50 U.S. states. Our quality systems and processes meet regulatory requirements and professional standards for testing.

Woman hugging her smiling toddler

When Neonatal Health Improves, We All Benefit

By identifying pregnancies that are at higher risk for a premature delivery, we’re able to offer patients and their providers the potential to intervene and improve outcomes. Reducing NICU admissions and length-of-stay, in addition to reductions in morbidity and mortality rates, can have tremendous emotional and financial benefit to families, healthcare providers, employers, and payers.

 %  reduction in NICU length-of-stay
The PREVENT-PTB trial demonstrated a statistically significant reduction up to 85% in median NICU length-of-stay for spontaneous preterm deliveries when higher-risk pregnancies identified by the PreTRM Test received risk-reduction interventions 1
Learn more
 %  reduction in NICU admissions
A HealthCore-led study projected a 10% reduction in required NICU admissions and overall hospital length-of-stay across all babies by 7% when modeled interventions were applied to pregnancies identified at higher risk by the PreTRM Test2
Learn more

The Future of Our Proprietary Technology Platform

As a leader in proteomic test development and validation, advanced bioinformatics, and multidimensional data analysis, we are committed to improving neonatal health by providing early and accurate risk predictors of pregnancy complications. In addition to our available PreTRM Test, we’re continuing to develop a robust pipeline of novel blood-based biomarker tests designed to uniquely address unmet needs in pregnancy related concerns. This enhanced risk predictor detection may provide patients and physicians with earlier opportunities for interventional treatment.

Potential future applications of our proteomic and bioinformatics technology platform may include:


Molecular Time-to-Birth

Gestational Diabetes

Fetal Growth Restriction


Postpartum Depression

Together, We Can Do Better

Revolutionizing prenatal care delivery requires team effort.
Our strategic partnerships provide the surround-sound expertise the task requires.


Leading Medical Experts and Practitioners

Professional Organizations

Patient Organizations

Payers and Employers

Our latest publications

Stay up-to-date on the latest content from Sera


  1. Branch, et al. Prediction and Prevention of Preterm Birth. Am J Perinatol. 2021. DOI https://doi.org/ 10.1055/s-0041-1732339.
  2. Grabner M, et al. Cost-Effectiveness of a Proteomic Test for Preterm Birth Prediction. Clinicoecon Outcomes Res. 2021.